Hepatitis A

Hepatitis A is a highly infectious virus that can cause inflammation of the liver. The virus is usually transmitted through food or water contaminated by human faeces or by direct contact with an infectious person. Hepatitis A is rare in the UK with most cases occurring in travellers who have recently visited countries where the disease is common.

Areas with high levels of infection include low-income countries that may have relatively poor sanitary conditions and hygiene practices. These areas include: the Indian subcontinent, Sub-Saharan and North Africa, parts of the Far East, South and Central America, and the Middle East.

Certain travellers are at increased risk of acquiring hepatitis A, including:

  • those who are staying with or visiting the local population
  • frequent and/or long-stay travellers to areas where sanitation and food hygiene are likely to be poor
  • those with existing medical conditions such as liver disease or haemophilia
  • men who have sex with men
  • people who inject drugs
  • those who may be exposed to the virus through their work
  • those going to areas of hepatitis A outbreaks who have limited access to safe water and medical care

Symptoms are often mild or absent in young children, but the disease becomes more serious with advancing age. Recovery can vary from weeks to months. Following hepatitis A illness, immunity is lifelong. Symptoms may include: fever, loss of appetite, jaundice (yellowing of the eyes and skin), malaise and nausea.


As the most common mode of infection in travellers is consumption of contaminated food or water. The risk of acquiring hepatitis A can be reduced by ensuring good personal hygiene and following advice on the prevention of food and water-borne diseases.

Hepatitis A vaccine

Several effective inactivated hepatitis A vaccines are available for travellers intending to visit areas where hepatitis A is common. Some of these vaccines are combined with either hepatitis B or typhoid.

Vaccine schedules

Vaccine (listed alphabetically) Schedule Age range
Combined hepatitis A and B
2 doses, given 6-12 months apart 1 to 15 years
AVAXIM 2 doses, given 6-12 months apart ≥ 16 years
AVAXIM Junior 2 doses, given 6-36 months apart 1 to 15 years
Epaxal (Discontinued) 2 doses, given 6-12 months apart Adults & children from ≥ 1 year
Havrix Monodose 2 doses, given 6-12 months apart ≥ 16 years
Havrix Junior Monodose 2 doses, given 6-12 months apart 1 to 15 years
Hepatyrix (Discontinued)
Combined hepatitis A and typhoid
1 dose followed by a single antigen hepatitis A vaccine 6-12 months later ≥ 15 years
Twinrix Adult
Combined hepatitis A and B
  • 3 doses, 0, 1, and 6 months
  • 4 doses, days 0, 7 and 21, 4th dose at 12 months
  • ≥ 16 years
  • ≥ 18 years
Twinrix Paediatric
Combined hepatitis A and B
3 doses, 0, 1 and 6 months 1 to 15 years
VAQTA Adult 2 doses, given 6-12 months apart ≥ 18 years
VAQTA Paediatric 2 doses, given 6-18 months apart 1 to 17 years
ViATIM (Discontinued)
Combined hepatitis A and typhoid
1 dose followed by a single antigen hepatitis A vaccine 6-12 months later ≥ 16 years

Length of protection

The duration of protection from a completed course of hepatitis A vaccine can be expected to be at least 25 years and probably indefinite. However, UK Health Security Agency recommend that until further evidence is available on persistence of protective immunity, a booster dose at 25 years is indicated for those at ongoing risk of hepatitis A. Specific advice should be sought for individuals with altered immune responses, an earlier booster may be recommended.


First published : 22 November 2018 Last updated : 14 July 2023

Explore more


Poliomyelitis is a potentially paralysing, vaccine preventable, viral infection transmitted through food or water contaminated by infected human faece

Updated: 19 February 2024

Zika virus

Zika virus infection is spread by day-biting mosquitoes

Updated: 07 February 2024


Malaria is a serious and sometimes fatal disease, transmitted by the bite of an infected mosquito occurring in many tropical regions of the world

Updated: 19 January 2024


Cryptosporidium is a parasite that causes an illness or disease called cryptosporidiosis that affects people and some animals

Updated: 11 January 2024


The typical symptoms of COVID-19 are fever and a cough that may progress to pneumonia causing shortness of breath and breathing difficulties

Updated: 07 September 2023

Recent News on Hepatitis A

Changes to the Country Information pages: Hepatitis A vaccine recommendations

NaTHNaC has reviewed and updated the hepatitis A country-specific information and vaccine recommendations

Updated: 31 August 2023

Recent Hepatitis A Outbreaks

11 October 2023

Hepatitis A in Slovakia

As of 6 October 2023, an outbreak of hepatitis A has been reported with cases in the Departments of Prešov (158 cases), RÚVZ Košice (139 cases), Michalovce (67) and Vranov nad Topl'ou (38).

Take usual precautions

21 July 2023

Hepatitis A in USA

As of 18 July 2023, there are 10 outbreak-associated cases of hepatitis A reported from 4 states (California, Hawaii, Oregon, and Washington), connected to the consumption of organic strawberries.

Take usual precautions

22 October 2021

Hepatitis A in New Caledonia

Between 1 January and 31 August 2021, 397 cases of hepatitis A have been reported. A total of 100 cases were reported in 2020.